Affiliation:
1. Center of Clinical Pharmacology, The Third Xiangya Hospital Central South University Changsha China
2. XiangYa School of Pharmaceutical Sciences Central South University Changsha China
3. Drug Clinical Trial Center, Center of Clinical Medical Research, Institute of Medical Innovation and Research Peking University Third Hospital Beijing China
4. Beijing Key Laboratory of Cardiovascular Receptors Research Peking University Third Hospital Beijing China
Abstract
The exposure to ticagrelor (BRILINTA) is higher in the East Asian population compared with the White population, thus, East Asians have an increased risk of bleeding. We developed a population pharmacokinetic (PopPK) model of ticagrelor based on a randomized 3 × 3 crossover study in healthy subjects. The area under the concentration‐time curve (AUC) of Chinese patients with acute coronary syndrome was simulated based on this model. Following this, eight machine learning (ML) methods were used to construct bleeding risk models. Variables included in the final bleeding risk model were age, hypertension, body weight, AUC, drinking status, calcium channel blockers, antidiabetic medications, β‐blockers, peripheral vascular disease, diabetes, transient ischemic attack, sex, and proton pump inhibitor. In terms of F1 scores and area under the curve of receiver operating characteristic curve (ROC‐AUC), the Random Forest model performed best among all models, with an F1 score of 0.73 and ROC‐AUC of 0.81. Moreover, the PopPK model and ML algorithm were used to bridge the real‐world data to build a bleeding risk prediction model based on drug exposure and clinical information. Using this model, a ticagrelor regimen that is associated with a lower risk of bleeding in individuals can be obtained. This model should be further validated prospectively in clinical settings.
Funder
Key Research and Development Program of Hunan Province of China
Subject
Pharmacology (medical),Pharmacology